KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Assets: 2013-2025

Historic Non-Current Assets for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $167.5 million.

  • Travere Therapeutics' Non-Current Assets fell 6.79% to $167.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.5 million, marking a year-over-year decrease of 6.79%. This contributed to the annual value of $177.4 million for FY2024, which is 3.07% up from last year.
  • Latest data reveals that Travere Therapeutics reported Non-Current Assets of $167.5 million as of Q3 2025, which was down 4.71% from $175.7 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Non-Current Assets peaked at $203.3 million during Q1 2023, and registered a low of $146.6 million during Q3 2023.
  • Its 3-year average for Non-Current Assets is $177.8 million, with a median of $177.4 million in 2024.
  • In the last 5 years, Travere Therapeutics' Non-Current Assets dropped by 23.39% in 2023 and then climbed by 22.54% in 2024.
  • Over the past 5 years, Travere Therapeutics' Non-Current Assets (Quarterly) stood at $193.8 million in 2021, then fell by 3.95% to $186.1 million in 2022, then decreased by 7.53% to $172.1 million in 2023, then grew by 3.07% to $177.4 million in 2024, then decreased by 6.79% to $167.5 million in 2025.
  • Its last three reported values are $167.5 million in Q3 2025, $175.7 million for Q2 2025, and $174.6 million during Q1 2025.